IMR Press / CEOG / Volume 43 / Issue 2 / DOI: 10.12891/ceog3078.2016

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women
Show Less
1 Research & Development Department, Ekuberg Pharma srl, Martano
2 Institute of Clinical Physiology, National Research Council, Lecce
3 Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, Faculty of Sciences, University of Salento, Lecce
4 Department of Diabetology, Poliambulatory “Cittadella della Salute”, Lecce (Italy)
5 Department of Obstetrics and Gynecology, Teaching Hospital of Ouagadougou, Ouagadougou (Burkina Faso)
6 Laboratory of Clinical Pathology, Poliambulatory “Cittadella della Salute” Lecce
7 Department of Obstetrics and Gynecology, Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Vito Fazzi Hospital, Lecce (Italy)
Clin. Exp. Obstet. Gynecol. 2016, 43(2), 198–202; https://doi.org/10.12891/ceog3078.2016
Published: 10 April 2016
Abstract

Background: Problems affecting the vaginal tract in diabetic women are very often neglected. The efficacy and safety of three gynecological treatments in diabetic women have been assessed. Materials and Methods: A single-blind randomized progressive trial on 48 diabetic women affected by vaginal dryness, dyspareunia, and recurrent Candida infections was carried out. The ICIQ Vaginal Symptoms (ICIQ-VS) questionnaire was administered. Results: The analysis of the parameters of ICIQ-VS questionnaire among the three groups showed significant difference only for “dragging pain” (p = 0.019) and “soreness” (p = 0.028). In all groups and for all parameters of the questionnaire, improvement of symptoms was observed. In particular, in Group 1 for all symptoms a highly significant difference was observed, to support the already known benefits of the products and of the proposed combination. Significant improvement was also observed in Group 2. Conclusions: The proposed treatment with DermoXENR Ultracalming Special for diabetics and DermoXEN R Vitexyl vaginal gel exert effective moisturizing and soothing action. Indeed, the aforementioned products have been proven effective for the main gynecological problems of diabetic women.
Keywords
Diabetes
vulvovaginal discharge
Vaginal dryness
Dermoxen®
Candida Albicans
Share
Back to top